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Summary
Germ-line mutations in DNA mismatch–repair genes im-
part a markedly elevated cancer risk, often presenting
as autosomal dominant hereditary nonpolyposis colo-
rectal cancer (HNPCC). However, there are no pathog-
nomonic features of HNPCC, not all gene carriers have
a family history of the disease, and families fulfilling the
Amsterdam criteria are relatively uncommon. Genetic
testing of probands with early-onset colorectal cancer,
irrespective of family history, is one approach that would
allow predictive genetic testing of at-risk relatives. We
cloned and sequenced hMSH2 and hMLH1 introns, to
optimize genomic sequencing. We then systematically
analyzed the entire hMSH2 and hMLH1 genes, by ge-
nomic sequencing and in vitro synthesized-protein–
truncation assay (IVSP), in 50 colorectal cancer patients
!30 years of age at diagnosis. To determine polymorphic
variants, 26 anonymous donors also were sequenced.
All subjects analyzed had at least 1 of 37 different poly-
morphic or pathogenic variants. IVSP complemented ge-
nomic sequencing, by detection of mutations not iden-
tified by genomic analysis. Fourteen cancer patients
(28%) had pathogenic mutations, and a number of other
variants also may have had a pathogenic significance
that remains to be elucidated. Tumor replication-error
status was useful in targeting sequencing efforts for this
cohort of young patients: sensitivity was 86%, specificity
73%, and positive and negative predictive values 63%
and 90%, respectively. These data indicate that an ap-
preciable proportion of young colon cancer probands
carry a germ-line mutation in a DNA mismatch–repair
gene.
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Introduction
Colorectal cancer (MIM 114500) is one of the most
common fatal cancers in developed countries and rep-
resents a significant public-health issue. The United
States and the United Kingdom are high-incidence coun-
tries, with ∼133,500 new cases and ∼55,300 deaths (Par-
ker et al. 1996b) in the United States and 30,941 new
cases and ∼17,000 deaths in the United Kingdom (Her
Majesty’s Stationery Office, United Kingdom Cancer
Registry Data) per year. The population lifetime risk is
1 in 25 in the United States and in northern Europe
(Sharp et al. 1993). In the United States, the annual
incidence increased from 98,757 in 1973 to 131,200 in
1997 (see the SEER [Surveillance, Epidemiology, and
End Results] database), while population-based cancer
registration in Scotland identified a 7% increased inci-
dence during the years 1981–90 (Sharp et al. 1993).
Identification of people predisposed to the disease would
allow targeting of effective preventative measures, with
the aim of reduction of the considerable cancer-related
mortality (Burke et al. 1997).
One group with a very high colorectal cancer risk
consists of those individuals who carry germ-line mu-
tations in genes that participate in DNA-mismatch re-
pair. hMSH2 (Fishel et al. 1993; Leach et al. 1993) and
hMLH1 (Bronner et al. 1994; Papadopoulos et al. 1994)
are involved most frequently, but mutations in hMSH6
(Akiyama et al. 1997) and in hPMS1 and hPMS2 (Ni-
colaides et al. 1994) also occur in a minority of cases.
Such mutations usually are associated with marked fa-
milial aggregation of colorectal, uterine, and other can-
cers constituting the clinically defined autosomal dom-
inant syndrome hereditary nonpolyposis colorectal
cancer (HNPCC; MIM 120435 and 120436) (Lynch et
al. 1993; Mary et al. 1994; Nystrom-Lahti et al. 1995;
Wijnen et al. 1995, 1997; Liu et al. 1996; International
Collaborative Group on HNPCC database). However,
an appreciable proportion of patients who have very
early–onset colorectal cancer but who do not fulfill prag-
matic criteria for HNPCC (Vasen et al. 1991) also carry
mismatch-repair–gene mutations (Liu et al. 1995; Dun-
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lop et al. 1997). Thus, restriction of genetic testing to
individuals from families fulfilling HNPCC criteria is
likely to exclude a significant fraction of gene carriers
in the general population. However, screening unselected
patients with sporadic cancer represents an enormous
workload and may provide a very low yield of mutation
carriers (Liu et al. 1995; Tomlinson et al. 1997; Wijnen
et al. 1997). The majority of kindreds analyzed for
hMLH1 and hMSH2 mutations have been selected spe-
cifically because of multiple affected cases; therefore, life-
time penetrance of mutations in these families is cor-
respondingly high, at ∼80% (Vasen et al. 1996).
However, when a population-based case-finding ap-
proach is used, penetrance appears to be lower than that
for families fulfilling HNPCC criteria (Dunlop et al.
1997). Concerns over penetrance and the potential effect
of ascertainment bias mean that the population preva-
lence of mutations in DNA mismatch–repair genes can-
not be estimated with any certainty. It is clear that the
definition of indications for genetic testing and the in-
terpretation of results are critical for hereditary cancer
syndromes (Giardiello et al. 1997). We set out to deter-
mine the prevalence of hMSH2 and hMLH1 alterations
in a cohort of 50 patients with extremely early onset of
colon cancer, irrespective of family history. We also
wished to determine the prevalence of variants in a con-
trol population, since polymorphisms could have a sig-
nificant confounding effect on strategies based on testing
at-risk individuals rather than probands.
Patients and Methods
Patients and Samples
A total of 76 subjects were studied: 50 unrelated Scot-
tish patients diagnosed with colorectal cancer at !30
years of age and 26 anonymous donors from the United
States. There were 15 male and 11 female anonymous
donors, who were cancer free at the time of sampling
and whose mean age was 41 years, which corresponded
well with the current age of the cancer patients. The
cancer cohort was identified retrospectively from cancer
registrations since 1970; thus, there is a potential sur-
vivorship bias, but our unpublished data do not suggest
that this is a major effect (see Discussion). None of the
study subjects were referred specifically because of a
family history of colon cancer. All cancer patients had
histologically confirmed colorectal cancer. Peripheral
blood was drawn, and DNA was purified from periph-
eral-blood leukocytes. Attempts were made to establish
lymphoblastoid cell lines from each cancer patient.
A detailed family history was obtained for all 50 pa-
tients with cancer diagnosed at !30 years of age, and
paraffin-embedded archival tumor material, along with
matched normal tissue, was obtained for 42 of these
patients. Pedigree ascertainment was rigorous and in-
cluded a patient interview or questionnaire, review of
hospital and pathology records, and verification through
birth, death, and marriage records for central Scotland.
At least three, and usually four, generations of ancestors
were traced for every proband, and in no cases were the
pedigrees connected. For every relative in each kindred,
current health/cancer status was ascertained, or the rel-
ative was determined to have died. Family history was
categorized as follows: 0  no family history of cancer;
1 relative with noncolorectal cancer; 2 relative with
colorectal cancer who does not fulfill the Amsterdam
criteria; and 3  nuclear family fulfills the Amsterdam
criteria for HNPCC (Vasen et al. 1991).
Analysis of Tumor Microsatellite Instability
Archival paraffin-embedded tumor tissue and
matched normal tissue (usually adjacent normal colon
tissue) were sectioned at 10 mm and were laid on glass
slides. A representative section was stained with hema-
toxylin/eosin and was examined by microscopy. Only
areas with 190% tumor were used in the analysis of
microsatellite instability. Adjacent normal tissue was
scraped off and discarded. Normal tissue was obtained,
in the same fashion, from a separate block when pos-
sible, ensuring that no tumor tissue was included in the
section. Depending on the size and cellularity of the sec-
tions, 3–15 sections were needed for tumor/normal tis-
sue. DNA was purified by use of the Qiagen Tissue Kit,
according to the manufacturer’s protocol.
As described elsewhere (Liu et al. 1995), 2–5 ml of
tumor and normal template solution was used in PCR
reactions, except that, in this study, all primers were
fluorescently labeled. The marker loci analyzed were
four (CA)n repeats (D2S123, D5S122, D5S346, and
D13S160) and four poly-A repeats (BAT25, BAT26,
BAT40, and Pax6-I253). The Pax6-I253 repeat is a poly-
A tract at the 3′ end of Pax6 in exon 13, and the primer
sequences are listed at http://www.hgu.mrc.ac.uk/Users/
Malcolm.Dunlop/MMRprim.htm. Analysis was per-
formed by use of an ABI 310 Automated Genetic An-
alyzer, with GeneScan software. Each tumor DNA sam-
ple was compared with matched normal DNA. At the
start of the analysis, tumor microsatellite instability was
defined as marker band shifts at a minimum of two loci.
Genomic Sequencing
DNA was extracted from peripheral blood by use of
the Nucleon DNA Extraction kit (Scotlab) or the Pure-
gene DNA Isolation kit (Gentra Systems), according to
the manufacturer’s instructions. We cloned and se-
quenced a number of introns from both hMLH1 and
hMSH2, to optimize genomic sequencing. Specific prim-
ers derived from these sequences and previously pub-
lished sequences (Kolodner et al. 1994) that worked well
in this study are listed at http://www.hgu.mrc.ac.uk/
Farrington et al.: Genetic Testing of Young Colon Cancer Patients 751
Users/Malcolm.Dunlop/MMRprim.htm. Each exon of
hMSH2 and hMLH1 was amplified by PCR using 40
ng of genomic DNA in a volume of 50 ml. Final reaction
concentrations were 1# PCR Buffer II (Perkin Elmer),
3.0 mM MgCl2 (or 1.5 mM, for hMSH2 exon 1), 0.2
mM dNTPs, 10 pmol of each specific oligonucleotide
primer, and 1.25 U Taq polymerase. Amplification was
hot started at 94C for 3 min, followed by 35 cycles of
94C for 20 s, 55C for 20 s, and 72C for 40 s. The
final reaction was extended at 72C for 10 min, followed
by storage at 4C. Cycle sequencing was performed by
use of the PRISM Ready Dye Terminator Cycle Sequenc-
ing kit with AmpliTaq DNA polymerase, FS (Taq-FS;
Perkin Elmer/Applied Biosystems), and Applied Bio-
systems DNA sequencer model 373A or 377 (Parker et
al. 1996a), according to the manufacturer’s instructions.
DNA sequence analysis was performed by use of Se-
quencher 3.0 software (Gene Codes), by comparison of
published genomic sequences of hMLH1 (Han et al.
1995; Kolodner et al. 1995; Genome Database accession
number 249617) and hMSH2 (Kolodner et al. 1994;
Genome Database accession number 203983) with those
from cancer cases or population donors.
In Vitro Synthesized-Protein–Truncation Assay (IVSP)
cDNA was generated by reverse transcription of RNA
purified from lymphoblastoid cell lines from the affected
index case. PCR amplification of the cDNA was used to
introduce a 17-bp consensus T7 promoter sequence and
a mammalian translation-initiation sequence in frame
with a unique hMLH1 or hMSH2 sequence. PCR primer
sequences and conditions were similar to those previ-
ously described in this article, with some modification
(Liu et al. 1995). Each gene was amplified in two or
three overlapping segments. Resultant PCR products
were used in a coupled transcription-translation reaction
(Promega) incorporating 2–5 mCi of 35S-methionine. La-
beled in vitro–transcribed protein products from the re-
action were heat denatured and were analyzed by use
of 8%, 10%, and 12% SDS-PAGE gels. Gels were
washed in fixative and were autoradiographed overnight
at room temperature. All samples showing truncated
protein products were reamplified independently, and an
additional IVSP analysis was performed, for confirma-
tion. For each analysis, normal control samples were run
in parallel, and the wild-type full-length protein was
noted. In most of the analyses, artifactual bands were
visible—presumably owing to internal initiation—since
these were visible in samples from normal controls.
Long-Range PCR
For long-range PCR of sample 817, the GeneAmp XL
PCR kit (Perkin Elmer) was used with forward primer
5′-GGC CAT TGT CAC AGA GGA TAA GA-3′ and
reverse primer 5′-ACA CAG CCC ACG AAG GAG TG-
3′. The reaction mixture contained ∼400 ng of genomic
DNA in a volume of 50 ml. Final reaction concentrations
were 1# PCR Buffer II (Perkin Elmer), 1.5 mM
Mg(OAc)2, 0.8 mM dNTPs, 40 pmol of each specific
oligonucleotide primer, and 4 U rTth DNA polymerase.
Amplification was hot started at 94C for 1 min, fol-
lowed by 26 cycles of 94C for 15 s and 68C for 10
min. The final reaction was extended at 72C for 10
min, followed by storage at 4C.
Results
Tumor Microsatellite Instability
We obtained paraffin-embedded archival matched tu-
mor and normal material from the respective pathology
departments for 42 of the cancer patients. Forty of these
samples could be amplified by PCR, to allow reliable
assessment of microsatellite-instability status, and 19
(48%) exhibited the instability phenotype. This pro-
portion is similar to that of our previous series of patients
!35 years of age (Liu et al. 1995) but is very much higher
than the 15% noted for a non–age-selected Scottish co-
hort of colorectal cancer patients (Bubb et al. 1996)
analyzed in our laboratories. Tumors exhibiting the in-
stability phenotype almost exclusively showed band
shifts at six or more markers. The lowest proportion of
markers showing band shifts was 4 (50%) of 8. Insta-
bility status related to the detection of germ-line mu-
tations, by genomic sequencing and by IVSP, for all 50
patients studied is shown in table 1. We could not detect
a mutation, by genomic sequencing, in one patient with
a microsatellite-unstable tumor; unfortunately, we also
were unable to obtain IVSP data, because the lympho-
blastoid cell line did not transform and the patient suc-
cumbed to malignant disease. Even when this case was
included in the analysis, it was clear that microsatellite
instability has considerable value in the prediction of
germ-line mismatch-repair–gene mutations (table 2). For
this very early–onset cohort, sensitivity of microsatellite-
instability status for mutation was 86% (12/14), and
specificity was 73% (19/26). Positive and negative pre-
dictive values were 63% (12/19) and 90% (19/21), re-
spectively. Microsatellite-instability status and family
history are summarized in table 3, with all five analyz-
able tumors from families fulfilling the Amsterdam cri-
teria exhibiting microsatellite instability. The proportion
of microsatellite-unstable tumors correlated with the
degree of family history, as has been noted by others
(Wijnen et al. 1997).
Genomic Sequencing
Using the combination of genomic sequencing and
IVSP analysis, we identified a total of 15 germ-line mu-
tations (table 4), and 5 of these mutations are novel
(patients 579, 815, 817, 830, and 1157). The relation-
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Table 1
Tumor Microsatellite Instability, Family History, and Germ-Line hMSH2/hMLH1 Mutations, for Young Cancer Probands
PATIENT
FAMILY
HISTORYa
TUMOR
MICROSATELLITE
INSTABILITY
IVSP GENOMIC SEQUENCING
hMSH2 hMLH1 hMSH2 hMLH1
825 1 POS POS NEG POS NEG
818 2 POS POS NEG POS NEG
528 0 POS ND ND POS NEG
830 2 POS ND ND POS NEG
814 2 POS POS NEG POS NEG
579 2 POS POS NEG POS/NEG NEG
815 2 POS NEG POS NEG POS
804 3 POS NEG POS NEG POS
533 3 POS NEG POS NEG POS
329 3 POS NEG NEG NEG POS
817 2 POS NEG POS NEG NEG
1052 3 POS NEG NEG NEG NEG
982 3 POS NEG NEG NEG NEG
889 1 POS NEG POS NEG NEG
871 0 POS NEG NEG NEG NEG
869 0 POS ND ND NEG NEG
862 1 POS NEG NEG NEG NEG
813 2 POS NEG NEG NEG NEG
615 1 POS NEG NEG NEG NEG
1157 0 NEG NEG NEG POS NEG
696 1 NEG NEG NEG NEG POS
1323 2 NEG NEG NEG NEG NEG
1279 2 NEG NEG NEG NEG NEG
1161 1 NEG NEG NEG NEG NEG
1012 1 NEG NEG NEG NEG NEG
964 0 NEG NEG NEG NEG NEG
887 0 NEG NEG NEG NEG NEG
876 0 NEG NEG NEG NEG NEG
860 1 NEG NEG NEG NEG NEG
822 0 NEG NEG NEG NEG NEG
819 1 NEG NEG NEG NEG NEG
812 2 NEG NEG NEG NEG NEG
809 1 NEG NEG NEG NEG NEG
757 0 NEG NEG NEG NEG NEG
737 1 NEG NEG NEG NEG NEG
649 0 NEG ND ND NEG NEG
622 1 NEG NEG NEG NEG NEG
551 0 NEG NEG NEG NEG NEG
510 1 NEG NEG NEG NEG NEG
106 1 NEG NEG NEG NEG NEG
1005 0 ND NEG NEG NEG NEG
983 0 ND NEG Incomplete NEG NEG
960 3 ND ND ND NEG NEG
824 2 ND ND ND NEG NEG
823 1 ND NEG NEG NEG NEG
816 1 ND ND ND NEG NEG
523 2 ND NEG NEG NEG NEG
324 2 ND ND ND NEG NEG
841 1 ) ND ND NEG NEG
559 0 ) NEG NEG NEG NEG
NOTE.—Designations and data for patients with pathogenic mutations are underlined. ND  not determined.
a Categories are described in Patients and Methods.
ship of family history and tumor microsatellite insta-
bility to mutation status is discussed in the relevant sec-
tions. Genomic sequencing initially only detected 12
(80%) of the 15 possible mutations. However, when
informed by IVSP data, genomic analysis characterized
a total of 14 (93%) mutations. However, it is important
to note that this improved detection rate only resulted
when complementary IVSP analysis was used.
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Table 2
Relationship of Tumor Microsatellite-Instability Status to Germ-Line
Mismatch-Repair–Gene Mutations
TUMOR
MICROSATELLITE-
INSTABILITY
STATUS
NO. OF TUMORS, BY GERM-
LINE–MUTATION STATUS
TOTALDetected Not Detected
Positive 12 7 19
Negative 2 19 21
Total 14 26 40
Table 3
Relationship of Family History and Tumor Microsatellite-Instability
Status to Germ-Line MLH1/hMSH2 Mutations, for Young
Colorectal Cancer Probands
TUMOR
MICROSATELLITE-
INSTABILITY
STATUS
NO. OF CASES, BY
FAMILY-HISTORY CATEGORYa
TOTAL0 1 2 3
All cases:
Positive 3 4 7 5 19
Negative 8 10 3 0 21
Not determined 3 3 3 1 10
Total 14 17 13 6 50
hMSH2:
Positive 2 1 4 0 7
Negative 12 16 9 6 43
hMLH1:
Positive 0 2 2 3 7
Negative 14 15 11 3 43
NOTE.—Mutation status is from combined genomic sequencing/
IVSP data. IVSP data were not available for 9 cases for hMSH2 and
10 cases for hMLH1 (table 1).
a Family history categories are described in Patients and Methods.
Two mutations are worthy of specific comment. The
mutation in patient 1157 disrupts the initiation codon
so that an in-frame methionine at codon 26 appears to
act as a surrogate transcription-start site, although stud-
ies indicate that the transcript is unstable. Characteri-
zation of the mutation identified in patient 579 proved
complex. Replicate hMSH2 IVSPs for patient 579 de-
tected a very short protein fragment, which could not
be explained on the basis of the HisrTyr mutation at
codon 639, identified by genomic sequencing. In view
of the IVSP results, we performed additional genomic
sequencing and eventually identified the second muta-
tion, at the splice acceptor site of exon 14 (table 4),
which initially had been missed. Using restriction-site
changes induced by each mutation, we traced both var-
iants through the family and showed that they reside on
the same allele. Extensive sequencing of reverse tran-
scription–PCR products revealed that this complex dou-
ble mutation results in an in-frame deletion of exons
12–14, thus accounting for the very short IVSP frag-
ment. A HisrTyr mutation at codon 639 has been re-
ported elsewhere (Leach et al. 1993; Liu et al. 1994)
and results in a surrogate splice donor site and a 92-bp
frameshift deletion of nt 1914–2006, generating a pre-
mature-termination codon 17-bp downstream of the
exon 13 splice acceptor site. To determine whether any
mRNA containing the 92-bp splice mutation reported
by Liu et al. (1994) was expressed in patient 579, we
serially amplified and sequenced overlapping fragments
from cDNA that included exons 11–15. We only de-
tected a wild-type sequence when the 3′ primer was 5′
of the splice acceptor site of exon 15. Hence, we have
established that the double mutation identified in patient
579 is distinct from that reported by Liu et al. (1994)
and that both mutations are required for deletion of
exons 12–14.
Sequencing in cancer patients and controls identified
a total of 37 variants, including presumed polymor-
phisms and pathogenic mutations (tables 4 and 5). The
polymorphisms are also of considerable interest, since
some of these polymorphisms possibly could contribute
to cancer predisposition. However, we did not consider
them pathogenic unless either there was a nonconser-
vative amino acid change or the variant arose at a con-
served sequence around a splice site. Among the 26 do-
nor DNAs, no previously published mutations were
found, but 6 donor DNAs had a total of four novel
variants (table 5). The significance of these changes is
uncertain and cannot be investigated, owing to the an-
onymity of the donors. The HisrTyr change at codon
718 of hMLH1 was present in three U.S. donors, but
we later discovered that two of these donors were
siblings.
IVSP
Lymphoblastoid cell lines were available from 41 of
the patients !30 years of age. Failure to transform usu-
ally was due to concurrent chemotherapy and/or ter-
minal cancer. In one case, we were not able to obtain
results from one segment of hMLH1, despite repeated
attempts (table 1). Thus, near-complete or complete
IVSP analysis of both genes was possible for 41 cases,
and 9 (22%) were positive (4 for hMSH2 and 5 for
hMLH1). Six of these cases were detected by screening
with genomic sequencing. For the two cases that were
found to be completely negative, by genomic sequencing,
we were prompted to perform additional detailed ge-
nomic analysis, as a result of reproducible IVSP and
cDNA findings. These studies showed that patient 817
has a large genomic deletion (see below). The other pa-
tient (889) showed a reproducible novel IVSP band but
no genomic DNA change and an apparent deletion of
the 3′ end of the gene, by cDNA sequencing. We have
not been able to delineate the genomic change in this
patient. In a third patient (579), there also was a dis-
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Table 4
Pathogenic hMLH1 and hMSH2 Mutations Identified in Young Colorectal Cancer Probands
Gene and
Patient Mutation Nucleotide Change
Effect on
Coding Sequence Location
hMLH1:
329 616delAAG Deletion of AAG at
1846–1848
Deletion of Lys616 Exon 16
533 IVS8–3delTA Deletion of TA at 6773 Splice mutation IVS 8
696 K618A AArGC at 1852–1853 LysrAla at 618 Exon 16
804 R659X CrT at 1975 ArgrStop at 659 Exon 17
815 IVS11GrA GrA at 1161 Splice mutation IVS 1
817* del exon 13 Deletion of ∼3 kb in-
volving IVS 12,
through exon 13 to
IVS 13
Deletion of codons
470–520 (exon 13)
IVS 12–13, exon 13
889 ) Not identified Truncation on IVSP Exons 12–19
hMSH2:
528* R406X CrT at 1216 ArgrStop at 406 Exon 7
579 H639Y
IVS131GrT
CrT at 1915
GrT at 2211
Double mutation results in
deletion of codons
588–820 (exons 12–14)
Exon 12,
IVS 13
814* Q601X CrT at 1801 GlnrStop at 601 Exon 12
818* Q252X CrT at 754 GlnrStop at 252 Exon 4
825* delCTGT Deletion of CTGT at
808–811
Deletion of codons
265–314 (exon 5)
Exon 5
830 R680X CrT at 2038 ArgrStop at 680 Exon 13
1157 M1L ArT at 1 New initiation at codon 26 Exon 1
Note.—Asterisks (*) designate mutations previously reported from our laboratories (Liu et al. 1995; Dunlop et al. 1997), but genomic
mutation of patient 817 has not been previously reported. IVS  intervening sequence.
crepancy between IVSP and genomic-sequencing data.
As discussed in the previous section, this patient has two
mutations, and the codon 639 HisrTyr change was de-
tected by sequencing. The splicing mutation initially was
missed by genomic sequencing but was identified by
IVSP analysis, which informed the subsequent genomic
and cDNA sequencing that fully characterized this com-
plex mutation.
In this study, when RNA purified from lymphoblas-
toid cell lines was used, IVSP was a robust method of
identifying detectable mutations. There were 11 muta-
tions that could have been identified by IVSP (including
the mutation in patient 889, which was detectable only
by IVSP). Although we did not have RNA from two
patients, sequencing and IVSP were complementary,
since IVSP identified 9 of 13 mutations (sensitivity 69%)
and genomic sequencing detected 12 of 15 mutations
(sensitivity 80%).
Long-Range PCR
Replicate IVSPs and cDNA sequencing of samples
from patient 817 reproducibly demonstrated a trunca-
tion in hMLH1 due to deletion of exon 13. However,
extensive genomic sequencing failed to identify the mu-
tation at the DNA level. Hence, we analyzed the intronic
region around exon 13 by long-range PCR, to determine
whether any large genomic deletion had removed that
exon completely. The forward primer was in exon 12
and the reverse in exon 14, resulting in an ∼15.5-kb
wild-type product. By use of this approach, patient 817
was shown to carry a genomic deletion of ∼3 kb, which
resulted in removal of exon 13 (fig. 1).
Family-History and Germ-Line–Mutation Status of the
Patients !30 Years of Age
Three (50%) of the six young probands from families
that fulfilled the Amsterdam criteria had germ-line mu-
tations. The nuclear family of patient 814 did not fulfill
these criteria and, so, was categorized as being in family-
history group 2. However, when several affected distant
relatives unknown to the nuclear family were identified,
as a result of research interests, it became clear that this
was a striking cancer family. There was a loose corre-
lation between family history and mutation prevalence,
but the association was not of practical value (table 3).
The prevalence of detectable mutations in each of the
family-history groups was 50% (3/6) for group 3
(HNPCC), 46% (6/13) for group 2, 18% (3/17) for
group 1, and 14% (2/14) for group 0. Thus, if analysis
had been restricted to the Amsterdam-criteria families,
only 21% of all mutations would have been identified.
Even if any first- or second-degree relative with colo-
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Table 5
hMSH2/hMLH1 Variants Considered to be Nonpathogenic Polymorphisms in Patients or Controls
GENE AND
VARIANT
NUCLEOTIDE
CHANGE
EFFECT ON
CODING SEQUENCE LOCATION
FREQUENCY
REFERENCEAllele 1 Allele 2 Percentage
hMLH1:
E/E13a 39GrA No change at Glu13 Exon 1 140 2 1.4
A/A125a 372ArG No change at Ala125 Exon 4 141 1 .7
IVS711GrC GrC at 58811 None apparent IVS 7 141 1 .7
I/V219a 654ArG lle or Val at 219 Exon 8 97 45 32.7 Tomlinson et al.
(1997)
IVS117insA 10397insA None apparent IVS 11 141 1 .7
IVS1314GrA GrA at 155814 None apparent IVS 13 140 2 1.4 Tannergard et al.
(1995)
IVS1419ArGa ArG at 166819 None apparent IVS 14 133 9 6.3 Buerstedde et al.
(1995)
L/L636 1908GrA No change at Leu636 Exon 17 141 1 .7
L/L653 1959GrT No change at Leu653 Exon 17 141 1 .7 Buerstedde et al.
(1995)
G/G706a 2118CrT No change at Gly706 Exon 19 137 5 3.5
H/Y718 2152CrT His or Tyr at 718 Exon 19 139 3 2.1
L/V729a 2184CrG Leu or Val at 729 Exon 19 141 1 .7
hMSH2:
IVS19CrGa CrG at 2119 None apparent IVS 1 121 21 14.8 Bubb et al. (1996)
K/K74a 219GrA No change at Lys74 Exon 2 141 1 .7
L/L191 574CrT No change at Leu191 Exon 3 139 3 2.1 Moslein et al.
(1996)
IVS99TrA TrA at 15119 None apparent IVS 9 21 121 85.2 Borresen et al.
(1995)
IVS1012ArGa ArG at 166112 None apparent IVS 10 54 88 62.0 Wijnen et al.
(1994)
IVS106TrCa TrC at 16616 None apparent IVS 10 0 142 100.0
IVS109GrAa GrA at 16629 None apparent IVS 10 141 1 .7
C/G641 121TrG Cys or Gly at 641 Exon 12 141 1 .7
IVS126TrCa TrC at 20066 None apparent IVS 12 133 9 6.3 Leach et al.
(1993)
I/V770 2308ArG lle or Val at 770 Exon 14 141 1 .7
NOTE.—Five patients with mutations that we had reported previously were not sequenced for all exons; thus, the total number of alleles
sequenced is 142 (45 patients and 26 controls). IVS  intervening sequence.
a Observed in cancer patients but not considered to be pathogenic, on the basis of the available evidence.
rectal or uterine cancer had been considered as an in-
dicator for gene analysis, only 64% of the mutations
would have been identified (tables 1 and 3).
Discussion
We report a systematic investigation of hMSH2 and
hMLH1, the two genes most commonly involved in he-
reditary predisposition to colorectal cancer. Detailed
analysis of the entire coding sequence of both genes was
completed for a total of 76 individuals, and we char-
acterized an appreciable number of variants. In all, there
were 37 variants, and 15 (41%) of these appear to be
pathogenic, on the basis of dramatic gene alterations
such as truncation, splice errors, short deletions, and
nonconservative amino acid changes. Fourteen (28%) of
the cancer patients had mutations, indicating that pa-
tients with very early–onset colorectal cancer merit anal-
ysis of DNA mismatch–repair genes. The large deletions
noted in patient 817 and possibly in patient 889 are of
some interest, since other, similar deletions that appear
to be mediated byAlu recombination have been reported
(Nystrom-Lahti et al. 1995; Mauillon et al. 1996).
Hence, when mutation screening fails to identify se-
quence changes in HNPCC families or in early-onset
cases, consideration should be given to methods for de-
tection of large deletions, such as the long-range PCR
used here, Southern blot analysis, or FISH using gene-
specific cosmids. Our genomic DNA–sequencing ap-
proach could not have detected promoter mutations that
might affect hMLH1 or hMSH2 expression, but, to date,
promoter alterations have been demonstrated only as
somatic events in tumor cells (Scherer et al. 1996; Kane
et al. 1997).
The sensitivity of genomic sequencing was 80%, and
that of IVSP was 64%. In this study, IVSP and genomic
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Figure 1 Long-range PCR of hMLH1 exons 12–14 (∼15 kb). Patient 817 shows a genomic deletion of ∼3 kb that includes exon 13 in
the hMLH1 gene. The asterisks (*) indicate four additional affected or at-risk family members who carry the same deletion allele detectable
by long-range PCR and the exon 13 deletion detected by reverse transcription–PCR analysis. Lane M, Genomic size marker.
sequencing were complementary, although RNA-based
mutation analysis raises practical problems for large-
scale mutation detection. Nonetheless, routine genomic
analysis of DNA fragments spanning intron/exon
boundaries would have missed an appreciable propor-
tion of all mutations in this patient cohort. For the pur-
poses of this study, our analysis was restricted to RNA
purified from lymphoblastoid cell lines. We and others
have experienced problems with RNA from peripheral
blood leukocytes (Kohonen-Corish et al. 1996) when
analyzing hMLH1 in particular. Since a relatively small
number of patients have very early–onset colorectal can-
cer, it may be practical to obtain RNA from other
sources, such as from skin biopsy or fresh surgical spec-
imens, although this also can be problematic.
The cohort of patients with onset of colorectal cancer
at !30 years of age who were analyzed for this study
constitute a highly select group. Colorectal cancer in this
age group accounts for !0.5% of all cancer registrations
in Scotland (Sharp et al. 1993). The patients were iden-
tified retrospectively—from a period of 23 years, to
1993—and, therefore, sampling could occur only if the
patients had survived. If survival is influenced by mu-
tation status, then our assessment of mutation preva-
lence may ultimately be biased. However, we found no
evidence of a survival effect for HNPCC gene carriers
in Scotland, for the time period in question (M.G.D.,
unpublished data). In addition, the group of patients in
this study developing cancer at !30 years of age had
been identified prospectively over the last 4 years, and
a number of gene carriers identified during this period
have since died from their disease. Hence, we believe
that the proportion (28%) of mutation carriers in the
cohort studied is representative. Although we have yet
to demonstrate clinical utility, patients who develop co-
lorectal cancer at !30 years of age seem to represent a
population in which analysis of DNA mismatch–repair
genes is worthwhile, regardless of family history.
In addition to contributing to the growing data on
the mutational spectra of hMSH2 and hMSH1, the poly-
morphic variants described here will have value as in-
tragenic markers for linkage studies in which mutations
cannot be identified in large families. It is important to
consider the prevalence of these variants when the pos-
sible pathogenic nature of sequence alterations identified
during predictive testing is assessed. All the samples an-
alyzed had one or more polymorphisms, when compared
with sequences stored in GenBank (accession nos.
U03911 and U04045 [for hMSH2 cDNA] and U07343
and U07418 [for hMLH1 cDNA]). Such a high preva-
lence may confound mutation-screening techniques such
as SSCP and may result in a high level of secondary
sequencing of polymorphisms. The benefit of the af-
fected-proband approach used in this study is that there
is de facto evidence of an association between the pu-
tative mutation and early-onset cancer. In cases for
which there is a dramatic mutation, such as a deletion
and/or a truncating mutation, there is no problem in the
assignment of cancer risk to that change. However,
amino acid substitutions do cause a dilemma in predic-
tive testing. Although not definitive, association of a mis-
sense mutation with early-onset cancer does contribute
considerable clinical significance if similar changes never
have been identified in healthy donors.
The microsatellite-instability phenotype in the tumors
from the young patients investigated in this study con-
sisted of band shifts at almost every locus examined.
This differs from the microsatellite instability observed
in non–age-selected cohorts in which one or twomarkers
may have been altered (Lothe et al. 1993; Bubb et al.
1996). Microsatellite instability was a useful predictor
of a germ-line mutation in this study group, with a pos-
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itive predictive value of 63%. However, reliance on the
instability phenotype as the sole indicator of the need
for mismatch-repair–gene analysis would have excluded
some patients who carry mutations (table 2). Of some
interest are the seven cases that are microsatellite unsta-
ble but for which we were unable to detect a mutation
in hMLH1 or hMSH2. These cases may be due to mu-
tations in other DNA mismatch–repair genes, such as
PMS1, PMS2, hMSH3, hMSH6, or other MLH/MSH
homologues, especially since three cases were associated
with a family history of cancer (tables 1 and 3).
Although a strong family history correlated with mu-
tation prevalence in this study, family history was not a
useful determinant of germ-line mutations, in practice.
In this study, the prevalence of mutations in families
fulfilling the Amsterdam criteria was 50%,which is iden-
tical to that in a Dutch study (Wijnen et al. 1997). An-
other study that included some HNPCC families show-
ing linkage to HMSH2 or hMLH1 identified 80% of
mutations (Liu et al. 1996); therefore, it is clear that
analysis of samples fromHNPCC families is highly likely
to identify mutations. However, in practice, recognition
of HNPCC families is confounded by lack of pathog-
nomonic features, deficiencies in family information,
adoption, early death of relatives that is due to unrelated
causes, and incomplete gene penetrance. Althoughmany
mutation carriers in this study did have one first- or
second-degree relative with colorectal or uterine cancer,
mutation screening of people with only one affected rel-
ative would be impractical, owing to the enormous
workload and the detection of variants of unknown sig-
nificance. Approximately 1% of the entire population
have either two first-degree relatives affected by colo-
rectal cancer or one relative affected at X45 years of
age (Dunlop and Campbell 1997), whereas a substan-
tially higher proportion have only one affected relative.
Thus, screening for mutations in DNA mismatch–repair
genes should concentrate not only on the relatively few
HNPCC families but also on early-onset cases, as they
arise, irrespective of family history and perhaps targeted
by tumor microsatellite-instability status. It is interesting
to note that 11 (25%) of 44 probands who came from
families that did not fulfil the Amsterdam criteria had
mutations. This differs substantially from the results of
two previous studies (Tomlinson et al. 1997; Wijnen et
al. 1997), in which mutations were detected in !6% and
!8% of cases, respectively. However, two reasons can
account for this. First, we used a combined approach of
genomic sequencing and IVSP, instead of exon screening
by SSCP and denaturing gradient-gel electrophoresis,
used in these previous studies, which would not have
detected mutations in patients 817 and 889. Second, the
extremely early age at onset in our cohort may explain
this discrepancy, since the average age of the probands
was less than that in the previous studies.
The feasibility of offering commercially available test-
ing for genetic diseases such as HNPCC, as well as the
possible outcomes from the results (Burke et al. 1997),
has been studied elsewhere (Plummer and Casey 1996).
The current use of commercial testing and the relation-
ship to genetic counseling for familial adenomatous
polyposis also has been described elsewhere (Giardiello
et al. 1997). Genetic testing for HNPCC could be offered
to anyone who chooses to be tested, or testing could be
restricted to individuals who can supply sufficient proof
that they fulfill stringent familial inheritance criteria.The
optimum testing criteria likely lie between these ex-
tremes, and the findings presented here suggest that con-
sideration should be given to the offering of genetic test-
ing to all index colon cancer patients !30 years of age.
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